PDCD1 and neoplasm: Additionally, the inhibition of CD73 improves the efficacy of anti-PD-1 and anti-CTLA-4 monoclonal antibodies [50], inhibits tumour growth, and reverses the exhausted T cell phenotype in mouse models [77].